What is coming next for vitiligo treatment?

Name: What is coming next for vitiligo treatment?
Creator: Ajith Dhati

This is where each vitiligo treatment in the pipeline actually stands today, and a place in it is not a treatment you can get yet.

Phase 2

Investigational zasocitinib
A Phase 2 study is recruiting people with nonsegmental vitiligo. Recruiting status can change.
Status checked 2026-08-04
Evidence · 1 source
- ClinicalTrials.gov (opens in a new tab) - Phase 2 vitiligo study is recruiting. Source dated or checked August 4, 2026. Confidence: moderate.
Investigational GIA632
A Phase 2 study is recruiting people with nonsegmental vitiligo. Recruiting status can change.
Status checked 2026-08-04
Evidence · 1 source
- ClinicalTrials.gov (opens in a new tab) - Phase 2 vitiligo study is recruiting. Source dated or checked August 4, 2026. Confidence: moderate.
Investigational LY4005130
A Phase 2 study is recruiting adults with nonsegmental vitiligo. Recruiting status can change.
Status checked 2026-08-04
Evidence · 1 source
- ClinicalTrials.gov (opens in a new tab) - Phase 2 vitiligo study is recruiting. Source dated or checked August 4, 2026. Confidence: moderate.

Phase 3

Investigational povorcitinib
Incyte reported that its two Phase 3 vitiligo studies met their main facial goal. At week 52, Incyte reported that 18.9% of participants reached at least 75% improvement in the facial score, against 6.8% with placebo in STOP-V1 and 3.1% with placebo in STOP-V2. Those are sponsor-reported topline percentages, not posted registry results or peer-reviewed findings. Incyte says regulatory applications are planned for 2027, which is a future filing plan rather than a completed filing or an approval.
Filing plan
Regulatory authorities not specified in the cited update: Incyte reported future regulatory applications are planned for 2027; the cited update is not a filing or approval. Plan checked 2026-08-17.
Status checked 2026-08-17
Full SteadySkin evidence profile: Investigational povorcitinib
Evidence · 3 sources
- Incyte (opens in a new tab) - Sponsor-reported Phase 3 topline: at week 52, 18.9% versus 6.8% with placebo reached at least 75% facial improvement in STOP-V1 and 18.9% versus 3.1% with placebo in STOP-V2, and regulatory applications are planned for 2027. Source dated or checked April 28, 2026. Confidence: moderate.
- ClinicalTrials.gov, U.S. National Library of Medicine (opens in a new tab) - STOP-V1 registry record: 467 participants, registered facial outcome, and no posted result tables when reviewed. Source dated or checked August 15, 2026. Confidence: moderate.
- ClinicalTrials.gov, U.S. National Library of Medicine (opens in a new tab) - STOP-V2 registry record: 450 participants, registered facial outcome, and no posted result tables when reviewed. Source dated or checked August 15, 2026. Confidence: moderate.
Litfulo (ritlecitinib)
Pfizer reports that two Phase 3 studies met facial and total-body repigmentation endpoints, in manufacturer topline form only; exact response percentages have not been released. The public participant counts do not agree. The trial registries record 607 people in TRANQUILLO and 1,571 in TRANQUILLO 2, while Pfizer's topline release described 1,567 for TRANQUILLO 2 within a 2,174-participant program. SteadySkin has not resolved that difference, so no single program total is presented here as settled. Pfizer describes global adult filings as planned, while the current US label is for severe alopecia areata rather than vitiligo.
United States
The current FDA label is for severe alopecia areata, not vitiligo. Status checked 2026-08-17.
Filing plan
Global adult filings: Pfizer reported filings are planned; the manufacturer topline is not a filing or approval. Plan checked 2026-08-17.
Status checked 2026-08-17
Full SteadySkin evidence profile: Litfulo (ritlecitinib)
Evidence · 6 sources
- ClinicalTrials.gov, U.S. National Library of Medicine (opens in a new tab) - TRANQUILLO registry record: 607 participants, completed status, and no posted result tables when reviewed. Source dated or checked August 16, 2026. Confidence: moderate.
- ClinicalTrials.gov, U.S. National Library of Medicine (opens in a new tab) - TRANQUILLO 2 registry record: 1,571 participants enrolled, which does not match the 1,567 described in the manufacturer topline release. Source dated or checked August 15, 2026. Confidence: moderate.
- Pfizer (opens in a new tab) - Sponsor-reported Phase 3 topline results from two studies described as a 2,174-participant program across 271 sites, with 1,567 in TRANQUILLO 2; exact response percentages were not released and adult filings are planned. Source dated or checked July 30, 2026. Confidence: moderate.
- US Food and Drug Administration (opens in a new tab) - Current FDA approval is for severe alopecia areata, not vitiligo. Source dated or checked June 30, 2026. Confidence: high.
- ClinicalTrials.gov (opens in a new tab) - Vitiligo Phase 3 study status is completed. Source dated or checked August 4, 2026. Confidence: moderate.
- ClinicalTrials.gov (opens in a new tab) - Vitiligo extension study remains active. Source dated or checked August 4, 2026. Confidence: moderate.
Scenesse (afamelanotide)
Being studied in an active Phase 3 trial with NB-UVB. The study is no longer recruiting. It is not approved for vitiligo.
Status checked 2026-08-04
Evidence · 1 source
- ClinicalTrials.gov (opens in a new tab) - Phase 3 study is active, not recruiting, and includes NB-UVB. Source dated or checked August 4, 2026. Confidence: moderate.

Approved for vitiligo in at least one jurisdiction

Rinvoq (upadacitinib)
The European Commission authorized Rinvoq for nonsegmental vitiligo in adults and adolescents from age 12 who are candidates for systemic therapy. The current US label does not include vitiligo, and the US indication remains under review.
European Union
Authorized for a defined nonsegmental-vitiligo population. Status checked 2026-08-14.
United States
The vitiligo indication is under FDA review and is not in the current US label. Status checked 2026-08-14.
Status checked 2026-08-14
Evidence · 4 sources
- AbbVie via PR Newswire (opens in a new tab) - AbbVie stated on July 29, 2026 that the nonsegmental-vitiligo indication remained under FDA review. Source dated or checked July 29, 2026. Confidence: moderate.
- AbbVie (opens in a new tab) - Submitted to the FDA and EMA for nonsegmental vitiligo. Source dated or checked February 4, 2026. Confidence: moderate.
- European Commission Union Register (opens in a new tab) - European Commission authorization for nonsegmental vitiligo. Source dated or checked July 24, 2026. Confidence: high.
- DailyMed, U.S. National Library of Medicine (opens in a new tab) - Current US label does not include vitiligo. Source dated or checked June 30, 2026. Confidence: high.
RECELL
An FDA-approved, in-office cell-harvesting device for repigmentation of stable vitiligo lesions. It is not right for everyone; ask a specialist.
United States
FDA approved for a defined stable-vitiligo population and professional setting. Status checked 2026-09-14.
Status checked 2026-09-14
Evidence · 1 source
- US Food and Drug Administration (opens in a new tab) - FDA approval includes repigmentation of stable vitiligo lesions. Source dated or checked June 16, 2023. Confidence: high.

Written and sourced by Ajith Dhati, a patient. How this site is written and checked.

Last updated August 20, 2026

Facts on this page verified August 17, 2026. Medications, prices, and trial status can change. We recheck them on a schedule. Tell us if something looks outdated.

Evidence · 3 sources

European Commission Union Register (opens in a new tab) - The European Commission authorized Rinvoq (upadacitinib) for nonsegmental vitiligo on July 24, 2026. Source dated or checked July 24, 2026. Confidence: high.
Pfizer (opens in a new tab) - Pfizer reported positive topline results from two Phase 3 Litfulo vitiligo studies; exact response percentages were not released and the public participant counts differ from the registry records. Source dated or checked July 30, 2026. Confidence: moderate.
Incyte (opens in a new tab) - Povorcitinib Phase 3 week-52 facial response percentages were reported by Incyte and regulatory applications are planned for 2027, not filed. Source dated or checked April 28, 2026. Confidence: moderate.

Read every headline as treatment news, not a cure promise

A pipeline medicine may become another treatment option. A trial result, filing, or approval would not promise permanent freedom from vitiligo.

That distinction does not make progress small. It keeps hope attached to what the source actually shows and leaves room to plan for follow-up, burden, and uncertainty.

Ask your care team Keep treatment, trial, and safety choices with the team that knows your health and goals.

What a pipeline status means for you

A status is a progress marker, not a forecast of whether a treatment will reach you.

Words such as early study, later study, filed, and approved describe different points in a long process. The source-linked tracker is the place for current drug names and status.

You do not need to put current care on hold because something newer may arrive later.

What you can do now

Separate the news you are following from the choice in front of you today.

Check the date and original source before sharing a headline.
Write down what interests you: how it is used, who was studied, access, or side effects.
Use the live trial finder if taking part in research interests you.
Keep treating, pause with a plan, or choose no active treatment for now.

Ask your care team Keep treatment, trial, and safety choices with the team that knows your health and goals.

How we handle changing news

Volatile facts belong in a dated record, not in timeless page copy.

Each tracker item should show when it was checked and link to the source. If a status cannot be confirmed, it does not appear as a current fact.

What should I ask at my next appointment?

Use these words as written, or change them to fit what you need.

I saw ___ in the pipeline. Does it change my choices today?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Would joining a study change or interrupt my current plan?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What option that is available now best matches my goal?
Saving keeps this on your device and needs JavaScript, which is off in this browser.